As of mid-2026, the biggest GLP-1 news is two pills: Novo Nordisk's oral Wegovy (oral semaglutide, approved December 2025) and Eli Lilly's Foundayo (orforglipron, approved April 2026). Behind them sit CagriSema, retatrutide and survodutide, all in late-stage trials and likely to reshape obesity treatment over the next few years.
What new GLP-1 drugs were approved recently?
Three notable changes hit the US market between late 2024 and 2026: two new oral approvals and one new indication for an existing injection.
Oral Wegovy (oral semaglutide 25 mg)
The FDA approved oral Wegovy — once-daily semaglutide 25 mg — on December 22, 2025, making it the first GLP-1 pill cleared for weight management. In the OASIS 4 trial, adherent participants lost about 16.6% of body weight, comparable to the injectable version (Novo Nordisk). It launched in the US in early January 2026. See oral Wegovy vs injectable Wegovy.
Foundayo (orforglipron) — Lilly's GLP-1 pill
Foundayo is Eli Lilly's small-molecule oral GLP-1, approved April 1, 2026 for adults with obesity or overweight with a weight-related condition. Unlike peptide pills, it has no food or water timing restrictions. In ATTAIN-1, participants lost up to about 12.4% of body weight at 72 weeks (Lilly). Pricing details are in our Foundayo coupon notes.
Zepbound for sleep apnea (new indication)
Not a new drug, but a notable expansion: in December 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever cleared for OSA (Lilly). More in our Zepbound guide.
New and pipeline GLP-1 drugs at a glance
| Drug | Molecule / class | Maker | Best-case weight loss | Status (mid-2026) |
|---|---|---|---|---|
| Oral Wegovy | Oral semaglutide 25 mg | Novo Nordisk | ~16.6% (OASIS 4) | Approved Dec 2025 |
| Foundayo | Orforglipron (oral GLP-1) | Eli Lilly | ~12.4% (ATTAIN-1) | Approved Apr 2026 |
| CagriSema | Cagrilintide + semaglutide | Novo Nordisk | ~22.7% (REDEFINE 1) | FDA filed Dec 2025 |
| Retatrutide | GLP-1 + GIP + glucagon | Eli Lilly | ~28.3% (TRIUMPH-1) | Phase 3 |
| Survodutide | GLP-1 + glucagon | Boehringer / Zealand | ~16.6% (SYNCHRONIZE-1) | Phase 3 |
What GLP-1 drugs are coming next?
Several next-generation candidates are in Phase 3 and could file for approval within the next year or two.
CagriSema (cagrilintide + semaglutide)
CagriSema pairs semaglutide with the amylin analogue cagrilintide in one weekly injection. Novo Nordisk filed with the FDA on December 18, 2025 after REDEFINE 1 showed about 22.7% weight loss at 68 weeks; a decision is expected around late 2026 (Novo Nordisk). See the CagriSema guide.
Retatrutide (triple agonist)
Retatrutide is Lilly's triple agonist, hitting GLP-1, GIP and glucagon receptors. Topline TRIUMPH-1 data in May 2026 showed about 28.3% weight loss at 80 weeks on the 12 mg dose (Lilly) — among the strongest results seen for an obesity drug. It is still investigational; read our retatrutide overview.
Survodutide (GLP-1 / glucagon)
Survodutide, from Boehringer Ingelheim and Zealand Pharma, is a GLP-1/glucagon dual agonist. In the Phase 3 SYNCHRONIZE-1 trial it produced about 16.6% weight loss at 76 weeks and is also being studied for MASH (liver disease) (Boehringer Ingelheim). Compare it in survodutide vs retatrutide.
Other candidates
Additional molecules in development include mazdutide (a GLP-1/glucagon agonist advancing chiefly in China) and several early-stage oral and combination therapies. Most are years from US availability and should be treated as experimental.
When will these pipeline drugs be available?
Of the unapproved candidates, CagriSema is closest — its FDA decision is expected around late 2026. Retatrutide and survodutide are likely filing in late 2026 or 2027, putting realistic US launches in 2027 or 2028 if trials and reviews go smoothly. None of these can be safely or legally bought today; products sold online as "retatrutide" or similar are unapproved research chemicals. For approved options you can actually get now, compare prices in our cheapest GLP-1 guide.
Why is the industry shifting to pills and multi-hormone drugs?
Two trends define the 2026 GLP-1 landscape. First, oral delivery: injection fatigue and access barriers drove the race for effective pills, which oral Wegovy and Foundayo have now delivered. Second, multi-hormone targeting: rather than GLP-1 alone, the most powerful new candidates add GIP (tirzepatide), glucagon (survodutide), both (retatrutide), or amylin (CagriSema). Combining pathways tends to increase weight loss, and the data increasingly reflect that hierarchy.
How do the newest drugs compare on weight loss?
Roughly ranked by average weight loss in pivotal trials, the triple agonist retatrutide (~28%) leads, followed by CagriSema (~23%), tirzepatide (around 21% in SURMOUNT-1), injectable and oral semaglutide (~15-17%), survodutide (~17%), and orforglipron (~12%). These figures come from different trials with different populations, so they are not strictly comparable, but they show the broad ordering. We track the molecule-versus-molecule matchups in orforglipron vs retatrutide and CagriSema vs retatrutide.
What side effects come with the newer GLP-1 drugs?
The new oral and combination drugs share the class's gastrointestinal profile: nausea, diarrhea, vomiting and constipation, generally worst during dose escalation. The dual and triple agonists can also raise heart rate modestly and, with a glucagon component, are watched for effects on blood sugar and liver enzymes. All approved incretin drugs carry the boxed thyroid C-cell tumor warning. Long-term safety for the newest molecules is still being established as trials read out.
Are compounded versions of new GLP-1 drugs legitimate?
With brand-name drugs expensive and sometimes scarce, compounded and grey-market versions of GLP-1s have proliferated. These are not FDA-approved, and quality varies. Experimental molecules such as retatrutide are sold online as "research chemicals" despite having no approval for human use. Approved products from a licensed pharmacy are the only quality-assured route. See our GLP-1 receptor agonist drug list for the approved landscape.
Should you wait for a newer GLP-1 drug?
It is tempting to hold out for whichever pipeline drug promises the most weight loss, but for most people the better move is to start with a proven, approved therapy and adjust later. The drugs available now — semaglutide and tirzepatide products, plus the two new oral options — are highly effective and backed by years of safety data. Pipeline candidates like retatrutide may eventually offer more, but timelines slip, approvals are not guaranteed, and access takes time after launch. The right choice depends on your diagnosis, insurance and tolerance, and is best made with a prescriber rather than by chasing headlines.
How do you get the newly approved GLP-1 pills?
Both new oral drugs require a prescription. Oral Wegovy and Foundayo launched through a mix of traditional pharmacies, the manufacturers' direct-to-patient platforms, and telehealth providers, with availability widening through 2026. Because they are pills rather than injections, they remove the needle barrier that keeps some people from starting therapy, though they carry the same warnings and gradual dose-escalation requirements as the injectables. Coverage is still uneven — many insurers cover obesity drugs inconsistently — so expect to confirm your benefits and compare cash and savings-card prices before filling. Whichever route you take, the medicine should come from a licensed pharmacy and a real prescriber, not an unverified online seller offering "research" products.
Frequently Asked Questions
What is the newest GLP-1 drug approved in 2026?
Foundayo (orforglipron), Eli Lilly's oral GLP-1 pill, was approved on April 1, 2026. It followed Novo Nordisk's oral Wegovy, approved in December 2025.
Is there a GLP-1 pill for weight loss now?
Yes — two. Oral Wegovy (semaglutide 25 mg) and Foundayo (orforglipron) are both FDA-approved oral GLP-1 medicines for weight management.
Is retatrutide approved yet?
No. Retatrutide is still in Phase 3 trials as of mid-2026. Its strong TRIUMPH-1 results make it a leading candidate, but it has not been approved or made commercially available.
Which upcoming GLP-1 drug causes the most weight loss?
In trials so far, the triple agonist retatrutide has shown the largest average weight loss (around 28% in TRIUMPH-1), ahead of CagriSema, survodutide and the approved single and dual agonists.
This article is for educational purposes and is not medical advice. Talk to a licensed healthcare professional before starting, stopping, or changing any medication.